Psychedelics Financing

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Seelos Therapeutics' $5.55M Public Offering As Stock Drop 35%
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More

Psychedelics Financing Recent News

Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal
Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) has announced a new underwritten offering of 66.66 million units to one of its largest institutional shareholders as well as new institutional investors.
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly 19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).
Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering
Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies
Swedish Foundation Supports Mental Health Innovation With New €3M Psychedelic Science Initiative
The Norrsken Foundation, a non-profit impact ecosystem “connecting founders with the capital, knowledge and network they need to make saving the world their business,” is launching a $3.22 (&e
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Morgan Stanley And TD Cowen Lead Financing Of Up To $285M For Psychedelics Company: Private Placement Backed By 'Select Group' Of Investors
Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group of healthcare specialist investors. 
MindMed Inks $50M Credit Facility Deal With K2 HealthVentures For An Additional Operational Year
Clinical-stage psychedelics biotech MindMed (NASDAQ: MNMD) has secured a new financing source by entering into a $50 million senior secured credit facility with K2 HealthVentures, an alternative investment firm focused on providing “flexible, long-term financing solut
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Cybin Closes Short-Lasting Overnight Public Offering With Top Issuance For $8.25M
Psychedelics biotech Cybin Inc. (NYSE: CYBN) closed its recently announced overnight marketed public offering with an aggregate of 24,264,706 units
Cybin Launches 3-Day Overnight Public Offering For Up To $8.25M, Suspends Prior Purchase Deal
Psychedelics company Cybin Inc. (NYSE: CYBN) announced an overnight marketed public offering of its units and confirmed its set pricing on an aggregate 24,264,706 Cybin units, at $0.34 each, for aggregate gross proceeds of $8,250,000.
Bright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ Compliance
Bright Minds Biosciences Inc. (NASDAQ: DRUG) is going for a consolidation of its common shares on a five-to-one basis, a plan approved by the company’s board of directors in June.
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic stress disorder (PTSD) and psilocybin to combat treatment-resistant depression.
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees
Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses
UK-based biotech firm Small Pharma Inc. (OTCQB: DMTTF) shared its financial outcomes for the fiscal year ended Feb. 28, plus pipeline updates.  Highlights:
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the report:
$100M Investment & Donation To Psychedelics Research From Toms Shoes Founder Blake Mycoskie
Several days prior to the FDA’s issuance of the draft guidance for clinical trials with psychedelics, Blake Mycoskie, founder of Toms Shoes pledged the new goal of donating a
Psyched: $75M In Federal Funds, Gov. Polis Opens MAPS Event, CNN's Show, Dock Ellis' LSD Pitch & More
Federal Psychedelics: $75M Grant Program

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved